Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Restructuring (2020 - 2023)

Historic Cash from Restructuring for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 4 years, with Q1 2023 value amounting to $2.6 million.

  • Lifecore Biomedical, Inc. \De\'s Cash from Restructuring fell 5134.62% to $2.6 million in Q1 2023 from the same period last year, while for Feb 2023 it was $34.1 million, marking a year-over-year decrease of 1860.74%. This contributed to the annual value of $1.4 million for FY2024, which is 11906.25% up from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Cash from Restructuring of $2.6 million as of Q1 2023, which was down 5134.62% from $563000.0 recorded in Q4 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Cash from Restructuring peaked at $34.9 million during Q2 2021, and registered a low of $563000.0 during Q4 2022.
  • Over the past 4 years, Lifecore Biomedical, Inc. \De\'s median Cash from Restructuring value was $2.1 million (recorded in 2021), while the average stood at $7.8 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Cash from Restructuring plummeted by 8308.08% in 2021, and later surged by 15465.96% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Cash from Restructuring (Quarter) stood at $1.1 million in 2020, then tumbled by 42.95% to $627000.0 in 2021, then dropped by 10.21% to $563000.0 in 2022, then skyrocketed by 355.77% to $2.6 million in 2023.
  • Its last three reported values are $2.6 million in Q1 2023, $563000.0 for Q4 2022, and $1.0 million during Q3 2022.